Search results
Results from the WOW.Com Content Network
Activation of a wide range of serotonin receptors by serotonin itself or by certain prokinetic drugs results in enhanced gastrointestinal motility. [3] Other prokinetic drugs may increase acetylcholine concentrations by stimulating the M 1 receptor which causes acetylcholine release, or by inhibiting the enzyme acetylcholinesterase which ...
[25] [26] [2] However, it is available in the United States for people with severe and treatment-refractory gastrointestinal motility problems under an expanded access individual-patient investigational new drug application. [25] An analogue of domperidone called deudomperidone is under development for potential use in the United States and ...
Generally, drugs outlined within the ATC code A should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Gastrointestinal system drugs .
Cisapride is a gastroprokinetic agent, a drug that increases motility in the upper gastrointestinal tract. It acts directly as a serotonin 5-HT 4 receptor agonist and indirectly as a parasympathomimetic. Stimulation of the serotonin receptors increases acetylcholine release in the enteric nervous system.
Decreasing intestinal motility prolongs the transit time of food content through the digestive tract, which allows for more fluid absorption; thereby alleviating diarrhea symptoms and improving stool consistency and frequency. [4] Unlike other opiates, loperamide does not cross the blood brain barrier, so there is minimal risk for abuse. [5]
The gastrocolic reflex or gastrocolic response is a physiological reflex that controls the motility, or peristalsis, of the gastrointestinal tract following a meal. It involves an increase in motility of the colon consisting primarily of giant migrating contractions, in response to stretch in the stomach following ingestion and byproducts of digestion entering the small intestine. [1]
GI peptides are signal molecules that are released into the blood by the GI cells themselves. They act on a variety of tissues including the brain, digestive accessory organs, and the GI tract. The effects range from excitatory or inhibitory effects on motility and secretion to feelings of satiety or hunger when acting on the brain.
The dual M1, M4 agonist xanomeline has been proposed as a potential treatment for schizophrenia. [ 5 ] [ 6 ] Xanomeline/trospium chloride was approved in the US in 2024. [ 7 ] Based on preclinical pharmacological and genetic studies, M1 predominantly modulates cognitive symptom domains and modestly regulates psychosis symptom domains.